Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results.

Purpose: To evaluate the short-term efficacy and safety of intravitreal bevacizumab for the treatment of retinal angiomatous proliferation.

Methods: Seventeen eyes from 16 patients with newly diagnosed retinal angiomatous proliferation underwent intravitreal injections of bevacizumab, 1.25 mg.